Health‐related quality of life · people (of any age) with CSOM
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Ear pain (otalgia) or discomfort or local irritation · people (of any age) with CSOM
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hearing · people (of any age) with CSOM
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious complications · people (of any age) with CSOM
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Suspected ototoxicity · people (of any age) with CSOM
1 finding from 1 review
Resolution of ear discharge ‐ measured at 1 to 2 weeks · adults with CSOM
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Resolution of ear discharge ‐ measured after 4 weeks · adults with CSOM
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality maximum · neonates and children with hospital‐acquired pneumonia
It is very uncertain whether cefepime changes all‐cause mortality Maximum compared with ceftazidime (very low certainty).
1 finding from 1 review
Health‐related quality of life Maximum · neonates and children with hospital‐acquired pneumonia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality (pneumonia-associated) · neonates and children with hospital‐acquired pneumonia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐serious adverse events Maximum · neonates and children with hospital‐acquired pneumonia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events maximum · neonates and children with hospital‐acquired pneumonia
It is very uncertain whether cefepime changes serious adverse events Maximum compared with ceftazidime (very low certainty).
1 finding from 1 review
Treatment failure Maximum · neonates and children with hospital‐acquired pneumonia
It is very uncertain whether cefepime changes treatment failure Maximum compared with ceftazidime (very low certainty).
1 finding from 1 review
Health‐related quality of life Maximum · neonates and children with hospital‐acquired pneumonia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality (pneumonia-associated) · neonates and children with hospital‐acquired pneumonia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐serious adverse events Maximum · neonates and children with hospital‐acquired pneumonia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality maximum · neonates and children with hospital‐acquired pneumonia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events maximum · neonates and children with hospital‐acquired pneumonia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment failure Maximum · neonates and children with hospital‐acquired pneumonia
It is very uncertain whether linezolid changes treatment failure Maximum compared with vancomycin (very low certainty).
1 finding from 1 review
All‐cause mortality at day 28 · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in all‐cause mortality at day 28 compared with placebo or standard of care alone (high certainty).
1 finding from 1 review